Hyperbaric Oxygen Therapy for Trigeminal Neuralgia: Current Evidence

Overview

Trigeminal neuralgia (TN) causes severe, electric-shock facial pain along the trigeminal nerve. Hyperbaric oxygen therapy (HBOT) involves breathing 100% oxygen at pressures >1 atm in a pressurized chamber.

Evidence Summary

• Small, uncontrolled studies report mixed results: some show pain reduction and quality-of-life improvement; others find no benefit.
• No randomized controlled trials (RCTs) exist to establish efficacy vs. placebo.
• Proposed mechanisms: Reduced nerve inflammation, improved oxygenation of compressed nerve, modulation of neuroinflammatory pathways.

Current Guidelines

• Not recommended as standard treatment by major neurology/pain societies (AAN, IASP).
• Considered experimental/investigational for TN.
• May be explored in refractory cases within clinical trials or compassionate use after multidisciplinary review.

Established TN Treatments

• First-line: Carbamazepine, oxcarbazepine.
• Second-line: Baclofen, lamotrigine, gabapentin.
• Procedural: Microvascular decompression (MVD), stereotactic radiosurgery (Gamma Knife), percutaneous rhizotomy (glycerol, balloon, radiofrequency).

Patients should discuss HBOT with their neurologist/pain specialist; insurance typically does not cover it for TN.